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A C C E P T E D M A N U S C R I P T Introduction Donepezil (DNP) is an acetylcholinesterase inhibitor that is widely used as a first-line drug throughout the world for mild to moderate Alzheimer's disease (AD) [1] [2] .
There is a large variability in the clinical response to DNP, partially because of patient genetic factors, which is the main obstacle for using donepezil clinically, especially in the Asian population [3] [4] [5] . As AD is a neurodegenerative disease, evaluating the efficacy of early stage drug treatment is important. However, there are no effective biomarkers to determine the efficacy of DNP [6] [7] [8] [9] [10] . The efficacy of DNP was previously hard to evaluate, and mostly depended on the Mini-mental State A C C E P T E D M A N U S C R I P T Examinatio (MMSE) or MoCa tests. These tests lack objectivity and are only available 3-4 months after patients start DNP treatment [5, [11] [12] [13] . There are no biomarkers available to evaluate the early efficacy of DNP.
It was reported that the ABCA1 gene is an important factor in AD pathogenesis. The ABCA1 gene is located on chromosome 9 and is linked to late-onset AD. ABCA1, an ATP-binding cassette A1 transporter, is a membrane-associated protein that acts as a cholesterol efflux pump in the cellular lipid removal pathway, which transfers cholesterol and phospholipids from the cell membrane to apolipoproteins (including APOE) to form nascent high-density lipoproteins (HDL) [14] [15] [16] [17] [18] [19] . Recent studies have also reported that DNP treatment reduced cholesterol accumulation in adult neural stem cells in vitro [20] , which indicates that DNP is related to cholesterol and ABCA1.
We therefore believe that the ABCA1 gene polymorphism may be related to the therapeutic response to DNP treatment for AD, although the association between ABCA1 gene polymorphisms and DNP efficacy remains unknown.
The aim of this study was to investigate the association between the ABCA1 gene polymorphism and the response to donepezil therapy in Han Chinese patients with Alzheimer's disease. As it was also reported that the APOE gene was related to DNP efficacy; in previous work, we have confirmed the association between APOE and the clinical response to DNP [13] . Here, we examined the combined effect of the ABCA1 and APOE genotypes on DNP efficacy to evaluate the possibility of using these genotypes to predict the clinical efficacy of DNP. (2) DNP was administered in combination with other drugs that are extensively metabolized by CYP2D6 or with other cognition-improving drugs [4, 22] .
Methods

Study population and study design
The MMSE was used to evaluate cognitive impairment in AD patients. The MMSE was used twice: before DNP treatment and after treatment with DNP for at least 3 months [20] . Blood samples were collected from the patients.
The demographic and clinical characteristics of these patients are shown in Table 1 .
Genotyping
Blood samples were collected into EDTA vacutainer tubes and stored at -80 °C until analysis. Genotyping of APOE and ABCA1 (rs2230806; rs2230808) were performed using PCR-LDR (ligase detection reaction, LDR). Genomic DNA was extracted from peripheral blood samples using an AxyPrep-96 DNA blood kit (Axygen, USA). The ABCA1 and APOE were identified by allele-specific PCR technology [13] . rs429358 and rs7412 were analyzed for APOE gene polymorphism, rs2230806 and rs2230808 was analyzed for ABCA1gene polymorphism.
Subjects with at least one APOE E3 allele were considered E3 carriers, and those with E2 or E4 alleles were considered E3 non-carriers.
Statistical analysis
p < 0.05 was taken to indicate statistical significance. Differences between genotypes were analyzed by Kruskal-Wallis tests, differences between two groups were analyzed by Mann-Whitney test, and the χ 2 test and Fisher's exact tests were used to compare
the rate of responders among different groups. Table 2 shows the ABCA1 polymorphisms observed in our patients. A significantly greater treatment effect in patients with ABCA1 rs 2230806 was observed (p = 0.001).
RESULTS
ABCA1 genotypes
Among these responders, patients with the GG allele (42.9%) responded best to DNP therapy and had the lowest proportion of non-responders (10.3%).
No significant difference in MMSE score was seen after at least 3 months of therapy in ABCA1 rs 2230808 patients (p = 0.109). The lowest proportion of responders had the rs2230808 AA allele, this study did not find a significant difference in the proportion of AA,AG and GG alleles between responders and non-responders. than that of non-responders (2.6%). This may be due to the low frequency of the APOE E2 and E4 alleles. E3 non-carriers with the GG genotype exhibited a trend toward the best therapeutic response to DNP. Table 4 shows the distribution of combined APOE and ABCA1 (rs2230808) patients.
Combined ABCA1 and APOE genotypes
Among the E3 carriers, patients with the AG and GG alleles had the same proportion of responders and non-responders, respectively, which is the reason that there were no significant differences among the three rs2230808 alleles.
In this study, patients with the ABCA1 rs2230806 GG genotype exhibited a better clinical response to DNP ( p = 0.001) compared to those with the AA and AG genotypes. We also genotyped ABCA1 rs 2230808, although these patients did not exhibit a significantly different response to DNP. DNP therapy should therefore be recommended for patients who are ABCA1 rs2230806 GG carriers. To the best of our knowledge, this is the first study to support this hypothesis in Han Chinese patients.
The relationship between ABCA1 polymorphisms and AD has recently become clear. Cholesterol metabolism has been widely implicated in the pathogenesis of AD [23] [24] . The ABCA1 gene plays a key role in cholesterol transport and APOE metabolism in the brain by facilitating the unidirectional efflux of free cholesterol and phospholipids from cells, and having a role in the formation of nascent HDL molecules, many studies explored the association between ABCA1 polymorphisms and AD, and this association has been confirmed [14] [15] [16] [17] [18] [19] .
However, few studies have focused on the association between the ABCA1 gene and DNP. Martinelli-Boneschi et al did a GWAS study for response to cholinesterase inhibitors in a sample of 176,they did not identify an effect of ABCA1 [25] . Our data showed that ABCA1 polymorphisms influence the clinical efficacy of DNP. Probable reasons may include the following: 1) DNP, which is an acetylcholinesterase inhibitor, has been shown to induce sAPP production [20, 26] ; 2) studies have shown that ABCA1 directly transports Aβ from the brain into the blood, while the cholesterol transporter ABCA1 neutralizes Aβ aggregation capacity in an APOE-dependent manner, facilitating Aβ subsequent elimination from the brain [16] ; 3) we therefore hypothesize that ABCA1 influences DNP efficacy via Aβ aggregation, which requires further study.
In our previous work evaluating the impact of APOE E3 in the therapeutic response to DNP in AD patients, we found that E3 non-carriers displayed a better clinical response to DNP therapy compared with that of E3 carriers [13] . In the present study, we explored the combined effects of the ABCA1 rs2230806 and APOE genes. It was reported that the expression of ABCA1 is regulated by the RXR-LXR is deeply related to APOE. We therefore believe that this may be the mechanism behind the crosstalk effect between the ABCA1 and APOE genes, and their influence on the clinical response to DNP. Our data showed that among the E3 non-carriers, patients with the ABCA1 rs2230806 GG genotype also had the trend of best therapeutic response to DNP (5-fold) compared with non-responders (Table 3 ). These data suggest that patients could have a prior choice of DNP therapy when they have both the ABCA1 rs2230806 GG and APOE E3 non-carrier genotype. However, a larger sample size study is needed to confirm this.
The strengths of this study are as follows: first, it is the first study to report the association between ABCA1 polymorphisms and the therapeutic response to DNP.
Second, this study provides data on the combined effects of ABCA1 rs2230806 polymorphisms and APOE in Han Chinese patients and supports the use of these markers in the prediction of the clinical efficacy of DNP therapy. Our data is most consistent with the view that ABCA1 variability contributes to the therapeutic response to DNP, although studies with a larger sample size are needed. 
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